About Third Arc Bio
Third Arc Bio is a clinical-stage biotech company developing multifunctional antibodies that generate immune synapses to precisely activate or inhibit T cells for oncology and immunology & inflammation diseases. Its lead program, ARC101, is a bispecific T cell engager targeting CLDN6 in Phase 1 trials for solid tumors. The company leverages two proprietary platforms — the ARCStim Platform for solid tumors and the ARCTag Platform for I&I — to deliver superior biologics with best-in-class T cell engagement.
Company details
Funding
Total raised
$217M
Last stage
Series A
Investors
Founders
Sanjaya Singh
PhD in molecular biology; co-inventor of Risankizumab (Skyrizi) and other immunology/oncology compounds; former Global Head of Janssen Biotherapeutics at J&J; founded Third Arc Bio in 2022.
LinkedInPeter F. Lebowitz
MD, PhD; joined Third Arc Bio as CEO in January 2024; former Global Head of Oncology R&D at Johnson & Johnson, where he oversaw 13 major drug approvals.
LinkedInJoe Erhardt
PhD; joined Third Arc Bio in 2023; formerly VP and Global Head of Oncology Discovery and External Innovation at Johnson & Johnson.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.